Bioatla Inc (BCAB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Bioatla Inc stock (BCAB) is currently trading at $0.15. Bioatla Inc PS ratio (Price-to-Sales) is 4.22. Analyst consensus price target for BCAB is $10.00. WallStSmart rates BCAB as Sell.
- BCAB PE ratio analysis and historical PE chart
- BCAB PS ratio (Price-to-Sales) history and trend
- BCAB intrinsic value — DCF, Graham Number, EPV models
- BCAB stock price prediction 2025 2026 2027 2028 2029 2030
- BCAB fair value vs current price
- BCAB insider transactions and insider buying
- Is BCAB undervalued or overvalued?
- Bioatla Inc financial analysis — revenue, earnings, cash flow
- BCAB Piotroski F-Score and Altman Z-Score
- BCAB analyst price target and Smart Rating
Bioatla Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Bioatla Inc (BCAB) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Bioatla Inc (BCAB) Key Strengths (1)
Revenue surging 31.60% year-over-year
Supporting Valuation Data
Bioatla Inc (BCAB) Areas to Watch (5)
Company is destroying shareholder value
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 4.2x annual revenue
Low institutional interest, mostly retail-driven
Fairly priced relative to book value
Bioatla Inc (BCAB) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 3.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 31.60%.
The Bear Case
The primary concerns are Return on Equity, Market Cap, Price/Sales. Some valuation metrics including Price/Sales (4.22), Price/Book (2.68) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -814.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -814.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 31.60% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BCAB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BCAB's Price-to-Sales ratio of 4.22x sits near its historical average of 4.22x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 4.22x set in Feb 2026, and 0% above its historical low of 4.22x in Feb 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Bioatla Inc (BCAB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Bioatla Inc is in a high-growth phase, prioritizing rapid expansion over margins.
Key Findings
Revenue growing at 32% YoY. This pace significantly outperforms most BIOTECHNOLOGY peers.
Free cash flow is -10M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Bioatla Inc maintain 32%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Bioatla Inc.
Bottom Line
Bioatla Inc is a high-conviction growth story with revenue accelerating at 32% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Bioatla Inc(BCAB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapies for the treatment of various cancers. The company is headquartered in San Diego, California.